EDAP Reports Continued Strong Growth in Third Quarter 2014


  • Revenues increased 27% year-over-year to EUR 20.3 million (USD 27.4 million) for the first nine months of 2014
  • HIFU revenue increased 114% year-over-year during first nine months of 2014
  • Positive operating income, excluding FDA-related costs, for three and nine months ended September 30, 2014
  • Solid financial profile with cash position of EUR 11.1 million (USD 14.0 million)
  • Three Focal One Systems sold during third quarter, demonstrates robust OUS demand for next-generation HIFU device
  • Recent FDA guidance on Ablatherm HIFU PMA submission provides clear U.S. regulatory path and opportunity.

Cyberonics Reports Fiscal 2015 Second Quarter Results

Continued strong earnings growth -- Achievement of regulatory milestones -- New one million share buyback

HOUSTON, Nov. 20, 2014  -- Cyberonics, Inc. (CYBX) today announced results for the quarter ended October 24, 2014.

Quarterly highlights[1]

Operating results for the second quarter of fiscal 2015 compared to the second quarter of fiscal 2014, and other achievements, include:

  • Worldwide net sales of $73.4 million, an increase of 5%;
  • Continued growth in international net sales to $13.5 million, and increased by 13% on a constant currency basis;
  • U.S. net sales reached a new high of $59.9 million;

Hamilton Thorne Comments on Unusual Market Activity

BEVERLY, MA and TORONTO, ON--( Nov 17, 2014) - Hamilton Thorne Ltd. (TSX VENTURE: HTL), a leading provider of precision laser devices and advanced image analysis systems for living cell applications in the fertility, stem cell and developmental biology research markets, today reported that, in view of the unusual market activity in the common shares of the Company, the Investment Industry Regulatory Organization of Canada (IIROC) has contacted the Company in accordance with its usual practice. While it ordinarily does not comment on market activity or market rumors, the Company confirmed that it is not aware of any material corporate developments that could account for the unusual trading activity.

Organovo Announces Commercial Release of the exVive3D™ Human Liver Tissue

SAN DIEGO, Nov. 18, 2014  -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, today announced the full commercial release of the exVive3DTM Human Liver Tissue for preclinical drug discovery testing.  Initially, clients will be able to access the technology through Organovo's contract research services program. This model is intended to provide human-specific data to aid in the prediction of liver tissue toxicity or ADME outcomes in later stage preclinical drug discovery programs.

Abiomed Announces Second Quarter Fiscal 2015 Revenue of $51.9 Million, Up 17% Over Prior Year

Abiomed on Track for Impella 2.5 and Impella RP FDA Approvals by February/March 2015

DANVERS, Mass., Oct. 30, 2014 -- Abiomed, Inc. (ABMD), a leading provider of breakthrough heart support technologies, today reports second quarter fiscal 2015 revenue of $51.9 million, an increase of 17% compared to revenue of $44.3 million for the same period of fiscal 2014. Second quarter fiscal 2015 GAAP net income was $3.8 million or $0.09 per diluted share, compared to GAAP net income of $1.1 million or $0.03 per diluted share for the prior year period.